FDA Approves Lembaz (Adrabetadex) to Reduce Death Risk in Infantile-Onset NPC

The U.S. Food and Drug Administration on Monday approved Lembaz (adrabetadex), the first therapy shown to improve survival in infantile-onset Niemann-Pick disease type C, a fatal neurodegenerative disorder, the agency announced.

The drug reduced the risk of death by 55% in treated patients compared with matched controls.

Approved for adults and children weighing at least 7 kilograms (about 15 pounds) whose neurological symptoms began before age 6, Lembaz addresses the underlying cholesterol trafficking defect that causes the disease — something no previously approved NPC therapy has been shown to do. The FDA estimates NPC affects roughly 1 in 150,000 people, and Beren Therapeutics, the drug’s developer, says about half of U.S. patients — roughly 475 children — have the infantile-onset form.

The stakes are stark.

FDA approves adrabetadex for infantile-onset Niemann-Pick type C
Photo: contemporarypediatrics.com

Lembaz Extends Life for Young Children

  • Lembaz is the first NPC medicine shown to extend life, and it can be given to very young, small children — down to about 15 pounds — whom existing drugs exclude.
  • It is delivered by injection into the spinal canal every two weeks by a trained provider, not as a pill or standard shot.
  • It carries a boxed warning for permanent hearing loss, so hearing must be tested before treatment and monitored throughout.

How the Survival Data Was Built

Because NPC is so rare, the FDA accepted a survival analysis across three clinical studies and an expanded access program, comparing 36 treated patients against a matched external control group. Treated patients had a median survival of 8.5 years versus 4.9 years in controls — a 55% reduction in the risk of death, the FDA said. The benefit held regardless of whether patients were also taking miglustat, a therapy used off-label in NPC.

The company’s announcement did not report confidence intervals or follow-up length.

Drug Bypasses Blood-Brain Barrier Intrathecally

Adrabetadex is a formulation of 2-hydroxypropyl-β-cyclodextrin (HPβCD), a sugar-based molecule that mobilizes cholesterol trapped inside neurons, compensating for defective NPC1 protein function. Because cyclodextrin does not readily cross the blood-brain barrier — the protective membrane that keeps most drugs out of the brain — it must be delivered intrathecally, directly into the cerebrospinal fluid.

The development path traces back to an NIH-led, open-label phase 1/2a trial published in The Lancet in 2017, in which 14 participants aged 4 to 23 with NPC1 received monthly intrathecal HPβCD for 12 to 18 months. Treatment slowed neurological progression compared with a natural history cohort, and hearing loss emerged as an expected adverse effect.

Existing Drugs Lack Mortality Benefit

Two therapies were already approved for NPC.

The Hearing Risk Behind the Boxed Warning

This has occurred in some patients whose hearing was normal before treatment. It is not known whether continuing dosing or dose reduction affects further loss.

Monitoring is intensive. Baseline testing includes pure tone audiometry, speech recognition testing, and tympanometry — a test of eardrum mobility. Doses are not increased if hearing loss exceeds set limits.

Beyond hearing, ataxia (loss of coordination) and fatigue, typically in the days after dosing, have occurred, including cases requiring hospitalization.

Comparing the Approved NPC Therapies

Therapy Approved (US) Eligibility Survival benefit shown?
Lembaz (adrabetadex) November 2026 ≥7 kg; symptoms began before age 6 Yes — 55% lower risk of death
Miplyffa (arimoclomol) September 2024 Age 2 and older, with miglustat No
Aqneursa (levacetylleucine) September 2024 ≥15 kg No

Early Treatment, and What Families Should Watch For

Provider Guides Dosing with Hearing Monitoring

Dosing decisions rest entirely with a trained provider guided by the audiologic monitoring schedule.

Beren Launches Support Programs for Families

Beren Therapeutics, which received approval through its subsidiary Mandos, LLC, along with a Priority Review Voucher, is launching a Caregiver Ambassador Program and LEMBAZ Family Support to help families find treatment sites, handle insurance, and obtain financial assistance, the company said. The drug received Breakthrough Therapy designation during development.

References

  • U.S. Food and Drug Administration. Press announcement, November 17, 2026.
  • Beren Therapeutics. Beren Therapeutics announces U.S. FDA approval of LEMBAZ (adrabetadex). Press release, November 17, 2026.
  • Ory DS, Ottinger EA, Farhat NY, et al. The Lancet. 2017;390(10104):1758-1768.
  • Rodriguez-Gil JL, Smith WE, Chang IJ, Mendelsohn BA. Genet Med Open. 2025;3:103462.

Treatment decisions for NPC should be made with a qualified specialist.

Photo of author

Health Desk

Health Desk at Archyde.

Hayden Panettiere’s Estranged Mom Skips Celebration of Life, Blames Ex-Boyfriend